HPV vaccination
- Method or treatment
One injection before the start of sexual life prevents most cervical cancers. It is one of the most powerful cancer-prevention tools medicine has.
See it in 3D: Cervix · External os
What it is
HPV vaccines contain virus-like particles made of the L1 capsid protein of human papillomavirus; they have no viral DNA and cannot cause infection. They induce neutralising antibodies that stop the virus entering the basal cells of the cervix and other epithelia. The bivalent vaccine covers types 16 and 18, which cause about 70% of cervical cancers; the quadrivalent adds 6 and 11 (genital warts); the nonavalent adds five more high-risk types. They prevent infection; they do not clear an existing one. WHO's 2022 position: the primary target is girls aged 9 to 14 before sexual debut, and a single dose gives protection comparable to two doses in healthy girls and young women. Colombia's national programme uses a single dose for healthy children and two doses only for immunosuppressed people (MinSalud, since 30 September 2023).
How it works and how well
- Efficacy against infection and precancer from the vaccine types is above 90% in people vaccinated before exposure; countries with high coverage have seen falls in cervical precancer and cancer.
- WHO schedule options (2022): one or two doses for girls aged 9 to 14 and for girls and women 15 to 20; two doses for women over 21; at least two, ideally three, for people who are immunocompromised or living with HIV.
- Boys and men can be vaccinated: it protects against genital warts and anal, penile and oropharyngeal cancers and reduces transmission.
- Colombia (MinSalud operational guidelines, 2024): a single dose for healthy children in the programme's age groups and two doses six months apart for immunosuppressed children; check the current national schedule for the ages covered.
- The vaccine is free in the national immunisation programme.
Step by step
- The vaccine's L1 proteins self-assemble into empty shells that look like the virus but carry no DNA.
- The immune system sees a dense, repetitive viral surface and makes high levels of neutralising antibody, even after one dose.
- Antibody seeps from blood onto the genital epithelium, especially at small breaks where the virus enters.
- Antibody binds the virus before it reaches the basal cells, so infection never starts.
- No persistent infection means no E6/E7 activity, no precancer and no cancer from the vaccine types.
The three vaccines
| Vaccine | HPV types | What it prevents |
|---|---|---|
| Bivalent | 16, 18 | About 70% of cervical cancers |
| Quadrivalent | 6, 11, 16, 18 | The same cancers plus most genital warts |
| Nonavalent | 6, 11, 16, 18, 31, 33, 45, 52, 58 | About 90% of cervical cancers plus warts |
Risks and who should not use it
- Common side effects: pain and swelling at the site, headache, and fainting in adolescents; vaccinate seated and observe for about 15 minutes.
- Contraindication: a severe allergic reaction to a previous dose or a vaccine component (the quadrivalent and nonavalent vaccines contain yeast proteins).
- Not recommended during pregnancy as a precaution; if given by mistake, no harm has been shown and the pregnancy needs no special measures.
- Large safety reviews (WHO Global Advisory Committee on Vaccine Safety) have found no link with autoimmune disease, infertility or chronic fatigue.
- It is not a treatment for warts, CIN or cancer, though it may reduce recurrence after treatment of high-grade lesions.
Next step / Follow-up
- Check the record at every contact with a child or adolescent aged 9 or over and vaccinate if a dose is missing, following the current national schedule.
- Answer parents' safety questions with clear data: the vaccine contains no virus DNA, and fainting is a needle reaction, not a vaccine injury.
- Vaccinated women still need cervical screening at the ages of the national programme.
- Report suspected serious adverse events to the national vaccine safety surveillance system.
- Offer vaccination to people with HIV or immunosuppression with the extra doses their schedule requires.
Common traps
- Stopping screening in vaccinated women: vaccines do not cover all high-risk types, and some women were already infected.
- Refusing to vaccinate a sexually active adolescent: she may not yet have met the vaccine types and still benefits.
- Thinking a single dose is a shortcut that gives weaker protection: WHO judged it comparable to two doses in healthy young people.
- Using it as treatment: it prevents new infections but does not clear existing ones.
Test yourself
Think of the answer, then tap the question to see it.
Why is HPV vaccination targeted at girls aged 9 to 14?
It prevents infection but does not clear it, so it works best before sexual debut; young adolescents also produce a strong immune response.
A 23-year-old vaccinated at 11 asks if she can skip cervical screening. What do you tell her?
No: the vaccine covers most but not all high-risk types, so she still needs screening at the ages of the national programme.
Can the HPV vaccine cause HPV infection or cancer?
No. It contains only empty L1 protein shells without viral DNA, so it cannot infect cells.
Elsewhere in DurgiPedia
- Giving vaccines safely and Colombia's PAI schedule
- HPV and cervical carcinogenesis
- Vaccine types: live, inactivated, subunit, toxoid, mRNA, vector
Connections
See it in 3D2
The structures of Durgical's 3D anatomy where it is found.
Microorganisms1
In Pharmacology1
← All of obstetrics and gynaecology
Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.
Sources: Human papillomavirus vaccines: WHO position paper, December 2022 (World Health Organization (Weekly Epidemiological Record), 2022); WHO updates recommendations on HPV vaccination schedule (World Health Organization, 2022); Human papillomavirus and cancer (fact sheet) (World Health Organization, 2024); Human Papillomavirus (StatPearls Publishing (NCBI Bookshelf), 2024); Alcance a los lineamientos técnicos y operativos para la vacunación contra el virus del papiloma humano (VPH) (Ministerio de Salud y Protección Social de Colombia, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
